Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
Total Funding: $330M
Total Funding: $84M
Total Funding: $72M
Total Funding: $66M
Total Funding: $460M
Total Funding: $140M
Total Funding: $50M
Total Funding: $550M
Total Funding: $80M
Total Funding: $640M
2010
Founder, CEO and managing director of a multi-stage healthcare and life sciences investment firm, and chief architect of its rigorous scientific and data-driven approach to investment analysis. Foresite Capital aims to address areas of great unmet clinical need over the long term by funding promising healthcare and life sciences businesses at all stages of their life cycles.
2001 - 2010
2001 - 2010
$1B healthcare venture capital group focussed on series A financings.
1997 - 2000
1997 - 2000
http://www.theravance.com/ and http://www.inva.com/
1994 - 1997
1994 - 1997
Built Healthcare Service Investment practice. Led investments in Amerigroup, Healtheon, CareSelect (through Intensiva), and Novamed.
1991 - 1997
1991 - 1997
Founded GelTex while finishing my Harvard degree, running the firm out of my garage for the first year. I recruited co-founder Professor George Whitesides from the Harvard Chemistry Department. Their product, Renvela, has helped more patients with renal failure than almost any drug in the world since its conception in 1991. The GelTex team also conceived of Cholestogel, which helped patients with high cholesterol that could not take other cholesterol reducing products. GelTex was sold to Genzyme, which was bought by Sanofi.
1991 - 1993
1991 - 1993
Primary architect of Prilosec GP strategy. Developed marketing campaign around promoting the use of Prilosec on patients with symptoms that had been treated with H2 antagonists (the previous market leaders). Pioneered using physician identified perscription data to focus marketing campaign on MDs that were top anti-ulcer prescribers.